Chitosan/fucoidan multilayer coating of gold nanorods as highly efficient near-infrared photothermal agents for cancer therapy
[Display omitted] •GNRs coated with the dual polymer is attractive for cancer therapy.•This is the first report on CS/F-GNRs as novel agents for photothermal therapy.•CS/F-GNRs under laser irradiation could completely ablate tumor in mice.•CS/F-GNRs as safe and highly efficient NIR photothermal agen...
Saved in:
Published in | Carbohydrate polymers Vol. 211; pp. 360 - 369 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.05.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | [Display omitted]
•GNRs coated with the dual polymer is attractive for cancer therapy.•This is the first report on CS/F-GNRs as novel agents for photothermal therapy.•CS/F-GNRs under laser irradiation could completely ablate tumor in mice.•CS/F-GNRs as safe and highly efficient NIR photothermal agents for cancer therapy.
Photothermal therapy (PTT) using chitosan/fucoidan multilayer coating of gold nanorods (CS/F-GNRs) has emerged as an alternative strategy for cancer therapy. In this study, biocompatible CS/F-GNRs were synthesized as a new generation of photothermal therapeutic agents for in vivo cancer treatments owing to their good biocompatibility, photostability, and strong absorption in the near-infrared (NIR) region. The CS/F-GNRs showed a good size distribution (51.87 ± 3.03 nm), and the temperature variation of the CS/F-GNRs increased by 54.4 °C after laser irradiation (1.0 W/cm2) for 5 min. The in vitro photothermal efficiency of CS/F-GNRs indicated that significantly more cancer cells were killed under laser irradiation at 1.0 W/cm2 for 5 min. On the 20th day of treatment, the MDA-MB-231 tumor cells in mice treated with CS/F-GNRs under laser irradiation had almost completely disappeared. Therefore, the biocompatible CS/F-GNRs have shown great promise as safe and highly efficient near-infrared photothermal agents for future cancer therapy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0144-8617 1879-1344 |
DOI: | 10.1016/j.carbpol.2019.01.010 |